Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model
Chronic stress and depressive-like behaviors in basic neuroscience research have been
associated with impairments of neuroplasticity, such as neuronal atrophy and synaptic loss …
associated with impairments of neuroplasticity, such as neuronal atrophy and synaptic loss …
Blinding and expectancy confounds in psychedelic randomized controlled trials
Introduction: There is increasing interest in the potential for psychedelic drugs such as
psilocybin, LSD and ketamine to treat several mental health disorders, with a growing …
psilocybin, LSD and ketamine to treat several mental health disorders, with a growing …
Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directions
Neurological disorders significantly outnumber diseases in other therapeutic areas.
However, develo** drugs for central nervous system (CNS) disorders remains the most …
However, develo** drugs for central nervous system (CNS) disorders remains the most …
Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms
Ketamine, a racemic mixture consisting of (S)-and (R)-ketamine, has been in clinical use
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …
Side-effects associated with ketamine use in depression: a systematic review
B Short, J Fong, V Galvez, W Shelker… - The Lancet Psychiatry, 2018 - thelancet.com
This is the first systematic review of the safety of ketamine in the treatment of depression
after single and repeated doses. We searched MEDLINE, PubMed, PsycINFO, and …
after single and repeated doses. We searched MEDLINE, PubMed, PsycINFO, and …
Targeting glutamate signalling in depression: progress and prospects
Major depressive disorder (MDD) is severely disabling, and current treatments have limited
efficacy. The glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine was …
efficacy. The glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine was …
[HTML][HTML] Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders
Current medication for anxiety disorders is suboptimal in terms of efficiency and tolerability,
highlighting the need for improved drug treatments. In this review an overview of drugs …
highlighting the need for improved drug treatments. In this review an overview of drugs …
International pooled patient-level meta-analysis of ketamine infusion for depression: in search of clinical moderators
Depression is disabling and highly prevalent. Intravenous (IV) ketamine displays rapid-onset
antidepressant properties, but little is known regarding which patients are most likely to …
antidepressant properties, but little is known regarding which patients are most likely to …
Ketamine for the treatment of major depression: a systematic review and meta-analysis
Background Intranasal esketamine has received regulatory approvals for the treatment of
depression. Recently a large trial of repeated dose racemic ketamine also demonstrated …
depression. Recently a large trial of repeated dose racemic ketamine also demonstrated …
Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms
S Kohtala - Pharmacological Reports, 2021 - Springer
Over the past 50 years, ketamine has solidified its position in both human and veterinary
medicine as an important anesthetic with many uses. More recently, ketamine has been …
medicine as an important anesthetic with many uses. More recently, ketamine has been …